16.79
+1.86
+(12.46%)
At close: April 15 at 9:27:56 PM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
257,352
257,352
615,995
228,291
23,146
Cost of Revenue
26,984
26,984
14,988
74,326
55,067
Gross Profit
230,368
230,368
601,007
153,965
-31,921
Operating Expense
458,884
458,884
348,368
161,903
107,932
Operating Income
-228,516
-228,516
252,639
-7,938
-139,853
Net Non Operating Interest Income Expense
38,996
38,996
23,846
1,785
-983
Pretax Income
-189,519
-189,519
276,485
-11,167
-140,511
Tax Provision
-12,440
-12,440
47,237
11
-20,723
Net Income Common Stockholders
-177,079
-177,079
229,248
-11,179
-119,789
Diluted NI Available to Com Stockholders
-177,079
-177,079
229,248
-11,179
-119,789
Basic EPS
-2.00
--
2.60
-0.13
-1.36
Diluted EPS
-2.00
--
2.59
-0.13
-1.36
Basic Average Shares
88,539.50
--
88,172.31
88,074.30
88,059.99
Diluted Average Shares
88,539.50
--
88,512.74
88,682.99
88,579.99
Total Operating Income as Reported
-228,514
-228,514
252,639
-17,336
-139,723
Total Expenses
485,868
485,868
363,356
236,229
162,999
Net Income from Continuing & Discontinued Operation
-177,079
-177,079
229,248
-11,179
-119,789
Normalized Income
-177,079
-177,079
229,248
-11,179
-119,782.18
Interest Income
40,845
40,845
34,228
2,535
--
Interest Expense
1,849
1,849
10,382
559
838
Net Interest Income
38,996
38,996
23,846
1,785
-983
EBIT
-187,670
-187,670
286,867
-10,608
-139,673
EBITDA
-187,670
-187,670
286,867
4,025
-126,566
Reconciled Cost of Revenue
26,984
26,984
14,988
74,326
55,067
Reconciled Depreciation
--
--
7,439
14,184
13,045
Net Income from Continuing Operation Net Minority Interest
-177,079
-177,079
229,248
-11,179
-119,789
Total Unusual Items Excluding Goodwill
--
--
--
--
-8
Total Unusual Items
--
--
--
--
-8
Normalized EBITDA
-187,670
-187,670
286,867
4,025
-126,558
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
--
--
--
--
-1.18
12/31/2021 - 11/2/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
RPD.MU Royalty Pharma plc
28.20
0.00%
HQ1.MU Oruka Therapeutics Inc. R
7.05
+6.02%
ARDX.MX Ardelyx, Inc.
105.50
0.00%
PROT Proteonomix, Inc.
0.0000
0.00%
7PO.F Poxel S.A.
0.4510
-11.39%
05Y.MU Vivoryon Therapeutics NV
1.7440
-4.49%
P0F.F Egetis Therapeutics AB (publ)
0.2955
-4.68%
ICY.HA Incyte Corp
52.14
+1.76%
BT3.BE Lineage Cell Therapeutics Inc
0.3800
-5.47%
2HA.F Spero Therapeutics, Inc.
0.6170
+16.64%